Literature DB >> 36078867

Diabetes Affects the Relationship between Heart Rate Variability and Arterial Stiffness in a Gender-Specific Manner.

Carla Serra1, Alessandro Sestu2, Veronica Murru2, Giulia Greco2, Matteo Vacca2, Angelo Scuteri1,3.   

Abstract

Background and Aims: Heart rate variability (HRV), i.e., the beat-by-beat fluctuations in heart rate (HR) reflecting the autonomic nervous system balance, is altered in patients with diabetes. This has been associated with arterial aging (stiffer arteries) and differs in men and women. The present study hypothesized that the impact of HRV on arterial aging, indexed as carotid-femoral pulse wave velocity (PWV), differs in a gender-specific manner and is affected by diabetes mellitus. Method: A total of 422 outpatients (187 women and 235 men) were studied. PWV was measured using the validated SphygmoCor device (AtCor Medical). Time-domain and frequency-domain parameters were measured to assess HRV.
Results: The prevalence of diabetes was 30.8% with a slight, but nonsignificant, greater prevalence in men. Both age and SBP were independent determinants of PWV in each of the four groups (men and women with or without diabetes). Low-frequency activity was inversely correlated with PWV. It was greater in women without diabetes, but it was not significant in men regardless of the presence of diabetes. Conclusions: Beyond age, blood pressure, and diabetes, impaired cardiac autonomic function assessed by determination of HRV was significantly associated with arterial aging. The association between lower sympathetic and parasympathetic activity and stiffer arteries was significant in women, but not in men.

Entities:  

Keywords:  arterial stiffness; diabetes; gender; heart rate variability; pulse wave velocity

Year:  2022        PMID: 36078867      PMCID: PMC9456306          DOI: 10.3390/jcm11174937

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.964


1. Introduction

An aging population is accompanied by emerging cognitive impairment [1] and a dramatic increase in the number of years lived with disability [2]. Searching for markers of aging [3], arterial stiffness, indexed as carotid–femoral pulse wave velocity (PWV), is considered a good proxy of large artery aging, from the early (accelerated) vascular aging (EVA) [4,5] to the “lower than average” arterial aging, i.e., healthy vascular aging (HVA) [5]. A greater PWV has been associated with greater blood pressure variability [6], multiple organ damage [7], increased cardiovascular (CV) morbidity and mortality [8], and cognitive impairment [9]. The prevalence of type 2 diabetes mellitus is increasing worldwide and significantly impacts on CV mortality [10]. Previous studies have shown that arterial stiffness is increased in people with diabetes [11]. To better characterize factors contributing to the modulation of arterial stiffness, we studied heart rate variability (HRV), i.e., the beat-by-beat fluctuations in heart rate (HR). HRV reflects the autonomic nervous system balance on the heart and is an indicator of CV risk [12] and mortality [13]. In general, increased cardiac sympathetic drive is detrimental, while increased cardiac parasympathetic activity is cardioprotective [14]. Alterations in HRV are common in diabetes [15] and have been linked with the severity of diabetes [15]. Of note, in diabetic patients, cardiac autonomic dysfunction has been associated with stiffer arteries independent of age and BP levels [16]. The aim of the present study was to characterize gender-differences with regard to the impact of HRV on arterial stiffness and whether they differ according to the presence of diabetes.

2. Methods

2.1. Study Population

The study population consisted of subjects who visited our Outpatient Clinic for evaluation of their blood pressure levels. Therefore, the study population resulted in a combination of subjects who resulted hypertensive and/or were undergoing a periodic follow-up of their condition and of subjects who were “unaffected”/healthy, often undergoing the visit as requested by their fitness center. Patients were excluded if they had cancer, acute myocardial infarction in the previous 6 months, hepatic or cardiac failure, serum creatinine ≥2 mg/dL, secondary hypertension, or thyroid disease. Additional exclusion criteria were a previous large vessel stroke and atrial fibrillation, since its presence interferes with the accuracy of aorta stiffness measurement. After informed consent was given, all patients underwent a medical history, a clinic visit, urinalysis, electrocardiography, and traditional CV risk factor measurements. We analyzed 422 patients presenting complete measurements of all the parameters investigated. All the measurements were collected at the same visit. These patients will represent the study population of the current study. Hypertension was defined as the intake of antihypertensive medications and/or if the average of three blood pressure (BP) measurements taken at 5 min interval was ≥140 for SBP or ≥90 mm Hg for DBP. Diabetes was defined as the previous diagnosis and/or use of antidiabetic medications. Body mass index (BMI) was calculated as body weight (kg)/height (m)2.

2.2. Assessment of Pulse Wave Velocity (PWV)

Aorta stiffness was assessed non-invasively by the carotid–femoral PWV. PWV was measured using the validated SphygmoCor device (AtCor Medical, Australia), whose validation and reproducibility have been previously published [17]. Pulse transit time was determined as the average of 10 consecutive beats. Transit time between carotid and femoral pressure waves was calculated using the foot-to-foot method. The distance traveled by the pulse wave was measured over the body surface subtracting the carotid location–sternal notch distance from the sternal notch–femoral site distance.

2.3. HRV Parameters

HRV was measured with the AtCor Medical HRV software to assess sympathetic/parasympathetic autonomic function. A standard 2 min electrocardiogram recording was performed with the patient in the supine position, with a regular and calm breathing pattern (5 min resting study) in a quiet room. Time domain measures are the mean and standard deviations of RR intervals recorded by the continuous electrocardiogram, where NN intervals represent all the RR intervals. The time domain of HRV was evaluated using the root mean square of successive differences between normal heartbeats (RMSSD) (m/s), which provides an estimate of the short-term components of HRV; the lower this vagal index, the greater the CV burden and the percentage of adjacent NN intervals that differ from each other by more than 50 m (pNN50) (%), which reflects alterations in autonomic function that are primarily vagally mediated and that are virtually independent of circadian rhythms. The frequency domain of HRV consists of the spectral analysis of a series of consecutive RR intervals in order to quantify sympathetic and vagal influences on the heart. The evaluated parameters were: power spectral density at the high-frequency (HF) range (0.15–0.4 Hz); power spectral density at the low-frequency (LF) range (0.04–0.15 Hz); the LF/HF ratio. Vagal activity is the major contributor to the HF component and to the time-domain parameters, while LF reflects both sympathetic and vagal activity; the ratio LF/HF is considered to mirror sympathovagal balance [13].

2.4. Statistical Analysis

All analyses were performed using SAS University Edition. PROC UNIVARIATE was adopted to test for normality. Both the Kolmogorov–Smirnov test and Shapiro–Wilk test revealed that the measured variables were not normally distributed; therefore, differences between men and women were compared by the Wilcoxon rank sum test or Mann–Whitney U test (PROC NPAIR1WAY wilcoxon). Multiple linear regression models were constructed to identify the association of HRV with PWV—separately in men and women, with and without diabetes—independent of age, hypertension, and BMI. SBP, DBP, HR, RMSDD, LF, HF, and LF/HF were all introduced as covariates. Backward elimination was adopted to achieve a more parsimonious model. An ANCOVA analysis was employed to test for interaction between sex and diabetes. A two-sided p value < 0.05 indicated statistical significance.

3. Results

The study population consisted of 422 patients (187 women and 235 men). The prevalence of diabetes was 30.8% with a slight, but nonsignificant, greater prevalence in men. As illustrated in Table 1, men were older, more frequently hypertensive, with greater BP and stiffer arteries than women.
Table 1

Characteristic of study population according to sex (median values and interquartile range).

Women (185)Men (237)GenderDifferencep
Age (years)61.0 (20.0)60.0 (27)62.5 (19)0.05
Women (%)43.8-----
Hypertension (%)62.151.970.00.001
Diabetes mellitus (%)30.826.034.60.06
BMI (Kg/m2)27.1 (7.1)26.8 (8.3)27.5 (6.4)0.62
SBP (mmHg)137.0 (23.0)134.0 (23.0)139.0 (19.0)0.01
DBP (mmHg)77.0 (14.0)75.0 (16.0)79.0 (14.0)0.001
HR (bpm)67.0 (16.0)67.0 (16.0)68.0 (16.0)0.86
pNN502.0 (10.8)2.2 (12.5)2.0 (10.0)0.75
rmSDD24.6 (27.1)25.0 (25.9)24.5 (26.1)0.72
LF727.0 (259.0)788.0 (288.0)734.0 (234.0)0.23
HF273.0 (258.0)292.0 (288.0)266.0 (234.0) 0.23
LF/HF ratio2.7 (2.5)2.4 (2.6)2.8 (2.5)0.23
PWV (m/s)9.3 (3.1)8.9 (2.6)9.8 (3.4)0.0001
Antihypertensive medication51.642.460.10.01
Antidiabetic medication27.824.330.30.05
Lipid-lowering therapy14.71117.60.05

BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; pNN50 = percentage of adjacent NN intervals that differ from each other by more than 50 m; rmSDD = root mean square of successive differences between normal heartbeats; LF = low-frequency domain in heart rate variability; HF = high-frequency domain in heart rate variability; and PWV = pulse wave velocity.

Multiple linear regression models were constructed to identify the significant determinants of arterial stiffness, indexed as PWV, according to sex and diabetic status. Regression model were adjusted for age, hypertension, and BMI. SBP, DBP, HR, RMSDD, LF, HF, and LF/HF were all introduced as covariates. Backward elimination of nonsignificant variables was adopted to achieve a more parsimonious model. The regression coefficient (with standard error) between the statistically significant factors in multivariable regression models and PWV are illustrated in Table 2. Both age and SBP were independent determinants of PWV in each of the four groups (men and women with or without diabetes) (Table 2). LF activity was inversely and significantly correlated with PWV in women, but not in men.
Table 2

Independent significant determinants of PWV in women and men with or without diabetes, identified by multiple regression analysis (regression beta coefficient +/− standard error) +.

WomenNO Diabetes(n = 136)WomenYES Diabetes(n = 49)MenNO Diabetes(n = 155)MenYES Diabetes(n = 82)
Age3.72 ± 0.970.000212.22 ± 4.890.029.32 ± 1.380.000116.78 ± 3.760.0001
SBP5.72 ± 1.130.00017.48 ± 2.820.025.24 ± 1.550.0015.87 ± 3.150.05
LF−0.039 ± 0.0180.05−0.337 ± 0.1500.030.018 ± 0.0160.280.002 ± 0.0050.72
Model R20.484 0.489 0.479 0.325

SBP = systolic blood pressure; LF = low-frequency domain in heart rate variability. + Controlling for age, hypertension, BMI, SBP, DBP, HR, RMSDD, LF, HF, and LF/HF.

To identify whether the impact of LF on PWV differed in men and women with or without diabetes, an ANCOVA analysis was conducted with interaction terms: sex × LF (does the correlation between LF and PWV differ in men and women?); diabetes × LF (does the correlation between LF and PWV differ in diabetic and nondiabetic patients?); sex × diabetes × LF (does the correlation between LF and PWV differ in men and women depending on their diabetic status?) (Figure 1).
Figure 1

Plots the slopes of the regression between LF activity, and PWV differed according to the presence of diabetes (significant interaction diabetes × LF). Additionally, LF activity showed a significant negative correlation with PWV in women (significant interaction sex × LF). The impact of diabetes on such a correlation differed in men and women (significant interaction sex × diabetes × LF); in fact, it was greater in women without diabetes, but it was not significant in men regardless of the presence of diabetes.

4. Discussion

In the present study, we showed that beyond age, blood pressure, and diabetes, impaired cardiac autonomic function assessed by determination of HRV was significantly associated with abnormal PWV. The association between lower sympathetic and parasympathetic activity and stiffer arteries was affected by the presence of diabetes, and it was significant in women, but not in men. High sympathetic activity has been associated with stiffer arteries in patients with and without diabetes [18]. This has been attributed, at least partially, to an increase in heart rate per se. However, in our study the significant association between lower LF activity and stiffer arteries was independent of heart rate levels. A previous study reported that in diabetic patients, the presence of cardiac autonomic neuropathy was associated with reduced aortic distensibility [19], an association that persisted significantly after controlling for the duration of diabetes [19]. Of note, the study selected diabetic patients without hypertension or macrovascular disease. Additionally, autonomic dysfunction was not further characterized with regards to specific domains of HRV. Factors modulating and/or impacting on HRV, arterial stiffness, and their relationship are complex. They include smoking, dyslipidemia, level of physical activity, comorbidities, medication for diabetes, and coexisting disease. The TODAY Study reported that glycemic control in younger diabetic subjects was associated with greater sympathetic activity (LF/HF) and stiffer arteries [16]. Additionally, glycemic and blood pressure controls were significantly associated with a worsening of HRV and arterial stiffening over time [20,21]. Gender differences have been reported for several conditions affecting arterial stiffness and/or the autonomic control of the heart: BP [6,22] and heart rate variability [23], walking speed [24], insulin resitance [25], and body weight and shape [26,27]. Concerning the observed gender differences in the association between HRV, namely lower low-frequency activity and PWV, it has been previously reported that, despite greater resting HR in women than in men, heart rate does not have the same predictive power for CV mortality and morbidity in women as it does in men [28,29]. There have been previously reports about gender differences in the “structure” of heart rate variability: women show less power in the low-frequency domain and greater power in the high-frequency domain than men, suggesting that the autonomic control of the heart and heart rate is characterized by a relative dominance of vagal and parasympathetic activity—despite greater mean HR—in women and by a greater sympathetic activity—despite lower resting HR—in men [30]. Characterization of mechanisms underlying the observed gender differences in the association between the low-frequency domain of HRV and arterial stiffness is beyond the design of the present study. A better characterization of the underlying mechanism may improve management and therapeutic indications and pharmacological treatment to reduce the CV burden in diabetes. The present study has some limitations. The first is the cross-sectional design that does not allow determination of a causal relationship between PWV and cardiac autonomic. Another limitation is that we did not adequately characterize metabolic control in diabetic patients nor the full spectrum of drugs taken by the recruited patients. Given the high percentage of patients with hypertension, several medications (beta- and alfa-blockers, for instance) could interfere with HRV and with its association with arterial stiffness. To summarize, the results of the present study suggest that the impact of HRV, i.e., the differences in the autonomic regulation of mean HR, on PWV, a parameter that reflects arterial aging, differs in men and women with or without diabetes. Research on HRV needs to emphasize and report sex differences in healthy as well as in population affected by CV conditions.
  30 in total

Review 1.  Gender, sex hormones and autonomic nervous control of the cardiovascular system.

Authors:  Anthony M Dart; Xiao-Jun Du; Bronwyn A Kingwell
Journal:  Cardiovasc Res       Date:  2002-02-15       Impact factor: 10.787

Review 2.  Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.

Authors:  Charalambos Vlachopoulos; Konstantinos Aznaouridis; Christodoulos Stefanadis
Journal:  J Am Coll Cardiol       Date:  2010-03-30       Impact factor: 24.094

Review 3.  Pulse wave velocity as a marker of cognitive impairment in the elderly.

Authors:  Angelo Scuteri; HongYu Wang
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 4.  Interaction between heart rate and heart rate variability.

Authors:  Jerzy Sacha
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-03-06       Impact factor: 1.468

5.  Gender specific profiles of white coat and masked hypertension impacts on arterial structure and function in the SardiNIA study.

Authors:  Angelo Scuteri; Christopher H Morrell; Marco Orru'; Majid AlGhatrif; Pier Sergio Saba; Antonio Terracciano; Liana Anna Pina Ferreli; Francesco Loi; Michele Marongiu; Maria Grazia Pilia; Alessandro Delitala; Kirill V Tarasov; David Schlessinger; Antonello Ganau; Francesco Cucca; Edward G Lakatta
Journal:  Int J Cardiol       Date:  2016-05-03       Impact factor: 4.164

6.  Relationship of Different Anthropometric Indices with Vascular Ageing in an Adult Population without Cardiovascular Disease-EVA Study.

Authors:  Leticia Gómez-Sánchez; Marta Gómez-Sánchez; Emiliano Rodríguez-Sánchez; Carmen Patino-Alonso; Rosario Alonso-Dominguez; Natalia Sanchez-Aguadero; Cristina Lugones-Sánchez; Ines Llamas-Ramos; Luis García-Ortiz; Manuel A Gómez-Marcos
Journal:  J Clin Med       Date:  2022-05-09       Impact factor: 4.964

7.  Aortic distensibility is reduced in subjects with type 2 diabetes and cardiac autonomic neuropathy.

Authors:  N Tentolouris; S Liatis; I Moyssakis; P Tsapogas; M Psallas; E Diakoumopoulou; V Voteas; N Katsilambros
Journal:  Eur J Clin Invest       Date:  2003-12       Impact factor: 4.686

Review 8.  Central sympathetic overactivity: maladies and mechanisms.

Authors:  James P Fisher; Colin N Young; Paul J Fadel
Journal:  Auton Neurosci       Date:  2009-03-06       Impact factor: 3.145

9.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Theo Vos; Abraham D Flaxman; Mohsen Naghavi; Rafael Lozano; Catherine Michaud; Majid Ezzati; Kenji Shibuya; Joshua A Salomon; Safa Abdalla; Victor Aboyans; Jerry Abraham; Ilana Ackerman; Rakesh Aggarwal; Stephanie Y Ahn; Mohammed K Ali; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Adil N Bahalim; Suzanne Barker-Collo; Lope H Barrero; David H Bartels; Maria-Gloria Basáñez; Amanda Baxter; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Eduardo Bernabé; Kavi Bhalla; Bishal Bhandari; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; James A Black; Hannah Blencowe; Jed D Blore; Fiona Blyth; Ian Bolliger; Audrey Bonaventure; Soufiane Boufous; Rupert Bourne; Michel Boussinesq; Tasanee Braithwaite; Carol Brayne; Lisa Bridgett; Simon Brooker; Peter Brooks; Traolach S Brugha; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Geoffrey Buckle; Christine M Budke; Michael Burch; Peter Burney; Roy Burstein; Bianca Calabria; Benjamin Campbell; Charles E Canter; Hélène Carabin; Jonathan Carapetis; Loreto Carmona; Claudia Cella; Fiona Charlson; Honglei Chen; Andrew Tai-Ann Cheng; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Manu Dahiya; Nabila Dahodwala; James Damsere-Derry; Goodarz Danaei; Adrian Davis; Diego De Leo; Louisa Degenhardt; Robert Dellavalle; Allyne Delossantos; Julie Denenberg; Sarah Derrett; Don C Des Jarlais; Samath D Dharmaratne; Mukesh Dherani; Cesar Diaz-Torne; Helen Dolk; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Karen Edmond; Alexis Elbaz; Suad Eltahir Ali; Holly Erskine; Patricia J Erwin; Patricia Espindola; Stalin E Ewoigbokhan; Farshad Farzadfar; Valery Feigin; David T Felson; Alize Ferrari; Cleusa P Ferri; Eric M Fèvre; Mariel M Finucane; Seth Flaxman; Louise Flood; Kyle Foreman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Belinda J Gabbe; Sherine E Gabriel; Emmanuela Gakidou; Hammad A Ganatra; Bianca Garcia; Flavio Gaspari; Richard F Gillum; Gerhard Gmel; Richard Gosselin; Rebecca Grainger; Justina Groeger; Francis Guillemin; David Gunnell; Ramyani Gupta; Juanita Haagsma; Holly Hagan; Yara A Halasa; Wayne Hall; Diana Haring; Josep Maria Haro; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Hideki Higashi; Catherine Hill; Bruno Hoen; Howard Hoffman; Peter J Hotez; Damian Hoy; John J Huang; Sydney E Ibeanusi; Kathryn H Jacobsen; Spencer L James; Deborah Jarvis; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Jost B Jonas; Ganesan Karthikeyan; Nicholas Kassebaum; Norito Kawakami; Andre Keren; Jon-Paul Khoo; Charles H King; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Ratilal Lalloo; Laura L Laslett; Tim Lathlean; Janet L Leasher; Yong Yi Lee; James Leigh; Stephen S Lim; Elizabeth Limb; John Kent Lin; Michael Lipnick; Steven E Lipshultz; Wei Liu; Maria Loane; Summer Lockett Ohno; Ronan Lyons; Jixiang Ma; Jacqueline Mabweijano; Michael F MacIntyre; Reza Malekzadeh; Leslie Mallinger; Sivabalan Manivannan; Wagner Marcenes; Lyn March; David J Margolis; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; Neil McGill; John McGrath; Maria Elena Medina-Mora; Michele Meltzer; George A Mensah; Tony R Merriman; Ana-Claire Meyer; Valeria Miglioli; Matthew Miller; Ted R Miller; Philip B Mitchell; Ana Olga Mocumbi; Terrie E Moffitt; Ali A Mokdad; Lorenzo Monasta; Marcella Montico; Maziar Moradi-Lakeh; Andrew Moran; Lidia Morawska; Rintaro Mori; Michele E Murdoch; Michael K Mwaniki; Kovin Naidoo; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Paul K Nelson; Robert G Nelson; Michael C Nevitt; Charles R Newton; Sandra Nolte; Paul Norman; Rosana Norman; Martin O'Donnell; Simon O'Hanlon; Casey Olives; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Andrew Page; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Scott B Patten; Neil Pearce; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; Konrad Pesudovs; David Phillips; Michael R Phillips; Kelsey Pierce; Sébastien Pion; Guilherme V Polanczyk; Suzanne Polinder; C Arden Pope; Svetlana Popova; Esteban Porrini; Farshad Pourmalek; Martin Prince; Rachel L Pullan; Kapa D Ramaiah; Dharani Ranganathan; Homie Razavi; Mathilda Regan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Kathryn Richardson; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Felipe Rodriguez De Leòn; Luca Ronfani; Robin Room; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Sukanta Saha; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; David C Schwebel; James Graham Scott; Maria Segui-Gomez; Saeid Shahraz; Donald S Shepard; Hwashin Shin; Rupak Shivakoti; David Singh; Gitanjali M Singh; Jasvinder A Singh; Jessica Singleton; David A Sleet; Karen Sliwa; Emma Smith; Jennifer L Smith; Nicolas J C Stapelberg; Andrew Steer; Timothy Steiner; Wilma A Stolk; Lars Jacob Stovner; Christopher Sudfeld; Sana Syed; Giorgio Tamburlini; Mohammad Tavakkoli; Hugh R Taylor; Jennifer A Taylor; William J Taylor; Bernadette Thomas; W Murray Thomson; George D Thurston; Imad M Tleyjeh; Marcello Tonelli; Jeffrey A Towbin; Thomas Truelsen; Miltiadis K Tsilimbaris; Clotilde Ubeda; Eduardo A Undurraga; Marieke J van der Werf; Jim van Os; Monica S Vavilala; N Venketasubramanian; Mengru Wang; Wenzhi Wang; Kerrianne Watt; David J Weatherall; Martin A Weinstock; Robert Weintraub; Marc G Weisskopf; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Sean R M Williams; Emma Witt; Frederick Wolfe; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Anita K M Zaidi; Zhi-Jie Zheng; David Zonies; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

10.  Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure.

Authors:  James E Sharman; Eoin O'Brien; Bruce Alpert; Aletta E Schutte; Christian Delles; Michael Hecht Olsen; Roland Asmar; Neil Atkins; Eduardo Barbosa; David Calhoun; Norm R C Campbell; John Chalmers; Ivor Benjamin; Garry Jennings; Stéphane Laurent; Pierre Boutouyrie; Patricio Lopez-Jaramillo; Richard J McManus; Anastasia S Mihailidou; Pedro Ordunez; Raj Padwal; Paolo Palatini; Gianfranco Parati; Neil Poulter; Michael K Rakotz; Clive Rosendorff; Francesca Saladini; Angelo Scuteri; Weimar Sebba Barroso; Myeong-Chan Cho; Ki-Chul Sung; Raymond R Townsend; Ji-Guang Wang; Tine Willum Hansen; Gregory Wozniak; George Stergiou
Journal:  J Hypertens       Date:  2020-01       Impact factor: 4.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.